These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. MOG Spectrum Disorders and Role of MOG-Antibodies in Clinical Practice. Hennes EM; Baumann M; Lechner C; Rostásy K Neuropediatrics; 2018 Feb; 49(1):3-11. PubMed ID: 28859212 [TBL] [Abstract][Full Text] [Related]
11. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690 [TBL] [Abstract][Full Text] [Related]
12. Seroprevalence of MOG and AQP4 Antibodies and Outcomes in an Indian Cohort of Pediatric Acquired Demyelinating Syndromes. Sankhyan N; Rawat A; Vyas S; Sahu JK; Bhagwat C; Madaan P; Saini L; Saini AG; Suthar R; Sukhija J; Jayashree M Neuropediatrics; 2022 Oct; 53(5):351-357. PubMed ID: 35617966 [TBL] [Abstract][Full Text] [Related]
13. Possible clinical role of MOG antibody testing in children presenting with acute neurological symptoms. Musso G; Nosadini M; Gallo N; Sartori S; Seguso M; Plebani M Neurol Sci; 2020 Sep; 41(9):2553-2559. PubMed ID: 32242290 [TBL] [Abstract][Full Text] [Related]
14. Clinical analysis of myelin oligodendrocyte glycoprotein antibody-associated demyelination in children: A single-center cohort study in China. Wang X; Zhao R; Yang H; Liu C; Wang W; Liu T; Lu C; Chen D Mult Scler Relat Disord; 2022 Feb; 58():103526. PubMed ID: 35063909 [TBL] [Abstract][Full Text] [Related]
15. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management. Ambrosius W; Michalak S; Kozubski W; Kalinowska A Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374173 [TBL] [Abstract][Full Text] [Related]
16. Clinical and MRI phenotype of children with MOG antibodies. Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801 [TBL] [Abstract][Full Text] [Related]
17. MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. Dos Passos GR; Oliveira LM; da Costa BK; Apostolos-Pereira SL; Callegaro D; Fujihara K; Sato DK Front Neurol; 2018; 9():217. PubMed ID: 29670575 [TBL] [Abstract][Full Text] [Related]
18. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders. Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911 [TBL] [Abstract][Full Text] [Related]
19. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis. Tajfirouz DA; Bhatti MT; Chen JJ Curr Neurol Neurosci Rep; 2019 Nov; 19(12):100. PubMed ID: 31773369 [TBL] [Abstract][Full Text] [Related]
20. Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome. Wendel EM; Thonke HS; Bertolini A; Baumann M; Blaschek A; Merkenschlager A; Karenfort M; Kornek B; Lechner C; Pohl D; Pritsch M; Schanda K; Schimmel M; Thiels C; Waltz S; Wiegand G; Anlar B; Barisic N; Blank C; Breu M; Broser P; Della Marina A; Diepold K; Eckenweiler M; Eisenkölbl A; Freilinger M; Gruber-Sedlmayr U; Hackenberg A; Iff T; Knierim E; Koch J; Kutschke G; Leiz S; Lischetzki G; Nosadini M; Pschibul A; Reiter-Fink E; Rohrbach D; Salandin M; Sartori S; Schlump JU; Stoffels J; Strautmanis J; Tibussek D; Tüngler V; Utzig N; Reindl M; Rostásy K; Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36229191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]